These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21781652)

  • 21. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.
    Brunel P; Lecaillon JB; Guyene TT; Imhof P; Ménard J
    Br J Clin Pharmacol; 1990 May; 29(5):503-9. PubMed ID: 2190629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydralazine dose-response curve analysis.
    Graves DA; Muir KT; Richards W; Steiger BW; Chang I; Patel B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):279-91. PubMed ID: 2231320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1983; 25(4):553-6. PubMed ID: 6653651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.
    Batchelor JR; Welsh KI; Tinoco RM; Dollery CT; Hughes GR; Bernstein R; Ryan P; Naish PF; Aber GM; Bing RF; Russell GI
    Lancet; 1980 May; 1(8178):1107-9. PubMed ID: 6103441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients.
    Jackson SH; Shepherd AM; Ludden TM; Jamieson MJ; Woodworth J; Rogers D; Ludden LK; Muir KT
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):624-8. PubMed ID: 1706804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.
    McQueen CA; Maslansky CJ; Glowinski IB; Crescenzi SB; Weber WW; Williams GM
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1269-72. PubMed ID: 6951172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the acetylator phenotype on amrinone pharmacokinetics.
    Hamilton RA; Kowalsky SF; Wright EM; Cernak P; Benziger DP; Stroshane RM; Edelson J
    Clin Pharmacol Ther; 1986 Dec; 40(6):615-9. PubMed ID: 3780123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.
    Facchini V; Timbrell JA
    Br J Clin Pharmacol; 1981 Apr; 11(4):345-51. PubMed ID: 7259927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of hydralazine and its main metabolites in slow and fast acetylators.
    Reece PA; Cozamanis I; Zacest R
    Clin Pharmacol Ther; 1980 Dec; 28(6):769-78. PubMed ID: 7438692
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
    Pullar T; Hunter JA; Capell HA
    Ann Rheum Dis; 1985 Dec; 44(12):831-7. PubMed ID: 2867746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.
    Hunyor SN
    Aust N Z J Med; 1975 Dec; 5(6):530-6. PubMed ID: 7224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability of standard and sugar-coated hydrallazine formulations in fast and slow acetylators [proceedings].
    Hawksworth GM; Morrice M; Petrie JC; Scott AK
    Br J Clin Pharmacol; 1980 Jan; 9(1):111P-112P. PubMed ID: 7356875
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects.
    Waller AR; Chasseaud LF; Taylor T; Darragh A; O'Kelly DA
    Biopharm Drug Dispos; 1979; 1(2):59-64. PubMed ID: 552862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of amonafide dosing based on acetylator phenotype.
    Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
    Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of the acetylator phenotype for the clinical use of dihydralazine.
    Siegmund W; Franke G; Biebler KE; Donner I; Kallwellis R; Kairies M; Scherber A; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S74-8. PubMed ID: 3842694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.